Company profile: SyntheticMR
1.1 - Company Overview
Company description
- Provider of innovative magnetic resonance imaging software that supports shorter exam times and delivers more information to clinicians. Products include SyMRI NEURO for quantitative MRI with contrast images, tissue segmentation, and volumetric measurements in a single scan; SyMRI MSK for musculoskeletal imaging with quantitative maps and contrast images; and MAGiC, a GE Healthcare version offering customizable MRI imaging solutions.
Products and services
- MAGiC: Customizable version of SyMRI IMAGE sold by GE Healthcare, offering customizable MRI imaging products for Magnetic Resonance Imaging
- SyMRI NEURO: Quantitative MRI tool delivering contrast images, tissue segmentation, and volumetric measurements in a single scan, aiding diagnosis and patient monitoring
- SyMRI MSK: Quantitative musculoskeletal MRI product delivering quantitative maps and contrast images in a single scan, supporting clinical and research applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SyntheticMR
BetterLife Pharma
HQ: Canada
Website
- Description: Provider of nutraceuticals and pharmaceuticals, engaged in production and commercialization, with product candidates including BETR-001, a non-hallucinogenic LSD derivative for psychiatric and neurological disorders; BETR-002, a hydrohonokiol derivative for benzodiazepine dependency, anxiety, and neurodegenerative disorders (oral capsule); and a viral infection candidate, including COVID-19, via subsidiary MedMelior.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BetterLife Pharma company profile →
MicroVention
HQ: United States
Website
- Description: Provider of catheter-based and minimally invasive neuroendovascular technologies for cerebral aneurysms and other neurovascular diseases, including delivery and detachment systems, access products, intraluminal devices, occlusion balloons, and flow diverters. Products include FRED X flow diverter, WEB Embolization System, BOBBY balloon guide catheters, and SOFIA Flow Plus aspiration catheter.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MicroVention company profile →
Balance Therapeutics
HQ: United States
Website
- Description: Provider of research and development focused on developing therapeutics to address conditions of intellectual disability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Balance Therapeutics company profile →
Allon Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical drug development for neurodegenerative diseases, with lead product Davunetide intranasal in Phase IIa clinical trials for Alzheimer's disease, schizophrenia cognitive impairment, and frontotemporal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allon Therapeutics company profile →
Trevena
HQ: United States
Website
- Description: Provider of an approved intravenous opioid analgesic (OLINVYK) for the management of acute pain in adults when alternative treatments are inadequate, and developer of GPCR-biased ligands, including TRV045 (oral S1P receptor; diabetic neuropathic pain and epilepsy; Phase 1), TRV250 (delta receptor; acute migraine; Phase 1), and TRV734 (oral mu receptor; maintenance treatment of opioid use disorder; Phase 1).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trevena company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SyntheticMR
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SyntheticMR
2.2 - Growth funds investing in similar companies to SyntheticMR
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SyntheticMR
4.2 - Public trading comparable groups for SyntheticMR
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →